-
A Geant4 Based Simulation Platform of the HollandPTC R&D Proton Beamline for Radiobiological Studies
Authors:
C. F. Groenendijk,
M. Rovituso,
D. Lathouwers,
J. M. C. Brown
Abstract:
A Geant4 based simulation platform of the Holland Proton Therapy Centre (HollandPTC, Netherlands) R&D beamline (G4HPTC-R&D) was developed to enable the planning, optimisation and advanced dosimetry for radiobiological studies. It implemented a six parameter non-symmetrical Gaussian pencil beam surrogate model to simulate the R&D beamline in both a pencil beam and passively scattered field configur…
▽ More
A Geant4 based simulation platform of the Holland Proton Therapy Centre (HollandPTC, Netherlands) R&D beamline (G4HPTC-R&D) was developed to enable the planning, optimisation and advanced dosimetry for radiobiological studies. It implemented a six parameter non-symmetrical Gaussian pencil beam surrogate model to simulate the R&D beamline in both a pencil beam and passively scattered field configuration. Three different experimental proton datasets (70 MeV, 150 MeV, and 240 MeV) of the pencil beam envelope evolution in free air and depth-dose profiles in water were used to develop a set of individual parameter surrogate functions to enable the modelling of the non-symmetrical Gaussian pencil beam properties with only the ProBeam isochronous cyclotron mean extraction proton energy as input. This refined beam model was then benchmarked with respect to three independent experimental datasets of the R&D beamline operating in both a pencil beam configuration at 120 and 200 MeV, and passively scattered field configuration at 150 MeV. It was shown that the G4HPTC-R&D simulation platform can reproduce the pencil beam envelope evolution in free air and depth-dose profiles to within an accuracy on the order of $\pm$5% for all tested energies, and that it was able to reproduce the 150 MeV passively scattered field to the specifications need for clinical and radiobiological applications.
△ Less
Submitted 30 May, 2023; v1 submitted 20 February, 2023;
originally announced February 2023.
-
Characterisation of the HollandPTC R&D proton beamline for physics and radiobiology studies
Authors:
M. Rovituso,
C. F. Groenendijk,
E. van der Wal,
W. van Burik,
A. Ibrahimi,
H. Rituerto Prieto,
J. M. C. Brown,
U. Weber,
Y. Simeonov,
M. Fontana,
D. Lathouwers,
M. van Vulpen,
M. Hoogeman
Abstract:
HollandPTC is an independent outpatient center for proton therapy, scientific research, and education. Patients with different types of cancer are treated with Intensity Modulated Proton Therapy (IMPT). In addition, the HollandPTC R&D consortium conducts scientific research into the added value and improvements of proton therapy. To this end, HollandPTC created clinical and pre-clinical research f…
▽ More
HollandPTC is an independent outpatient center for proton therapy, scientific research, and education. Patients with different types of cancer are treated with Intensity Modulated Proton Therapy (IMPT). In addition, the HollandPTC R&D consortium conducts scientific research into the added value and improvements of proton therapy. To this end, HollandPTC created clinical and pre-clinical research facilities including a versatile R&D proton beamline for various types of biologically and technologically oriented research. In this work, we present the characterization of the R&D proton beam line of HollandPTC. Its pencil beam mimics the one used for clinical IMPT, with energy ranging from 70 up to 240 MeV, which has been characterized in terms of shape, size, and intensity. For experiments that need a uniform field in depth and lateral directions, a dual ring passive scattering system has been designed, built, and characterized. With this system, field sizes between 2x2 cm2 and 20x20 cm2 with 98% uniformity are produced with dose rates ranging from 0.5 Gy/min up to 9 Gy/min. The unique and customized support of the dual ring system allows switching between a pencil beam and a large field in a very simple and fast way, making the HollandPTC R&D proton beam able to support a wide range of different applications.
△ Less
Submitted 20 February, 2023;
originally announced February 2023.
-
Secondary radiation measurements for particle therapy applications: nuclear fragmentation produced by $^4$He ion beams in a PMMA target
Authors:
M. Marafini,
R. Paramatti,
D. Pinci,
G. Battistoni,
F. Collamati,
E. De Lucia,
R. Faccini,
P. M. Frallicciardi,
C. Mancini-Terracciano,
I. Mattei,
S. Muraro,
L. Piersanti,
M. Rovituso,
A. Rucinski,
A. Russomando,
A. Sarti,
A. Sciubba,
E. Solfaroli Camillocci,
M. Toppi,
G. Traini,
C. Voena,
V. Patera
Abstract:
Nowadays there is a growing interest in Particle Therapy treatments exploiting light ion beams against tumors due to their enhanced Relative Biological Effectiveness and high space selectivity. In particular promising results are obtained by the use of $^4$He projectiles. Unlike the treatments performed using protons, the beam ions can undergo a fragmentation process when interacting with the atom…
▽ More
Nowadays there is a growing interest in Particle Therapy treatments exploiting light ion beams against tumors due to their enhanced Relative Biological Effectiveness and high space selectivity. In particular promising results are obtained by the use of $^4$He projectiles. Unlike the treatments performed using protons, the beam ions can undergo a fragmentation process when interacting with the atomic nuclei in the patient body. In this paper the results of measurements performed at the Heidelberg Ion-Beam Therapy center are reported. For the first time the absolute fluxes and the energy spectra of the fragments - protons, deuterons, and tritons - produced by $^4$He ion beams of 102, 125 and 145 MeV/u energies on a poly-methyl methacrylate target were evaluated at different angles. The obtained results are particularly relevant in view of the necessary optimization and review of the Treatment Planning Software being developed for clinical use of $^4$He beams in clinical routine and the relative benchmarking of Monte Carlo algorithm predictions.
△ Less
Submitted 29 August, 2016;
originally announced August 2016.
